[关键词]
[摘要]
目的 探讨重组人尿激酶对急性ST段抬高型心肌梗死的临床疗效及炎症因子的影响。方法 选取2016年3月-2018年3月在三门峡市中心医院住院治疗的ST段抬高型心肌梗死患者110例,采用随机数字法分为研究组(55例)和对照组(55例),对照组患者给予常规治疗,研究组患者在常规治疗的基础上给予重组人尿激酶进行治疗,比较两组患者的血管再通率及主要不良心血管事件(MACE)的发生率,并测定治疗前后超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、单核细胞趋化蛋白(MCP-1)、人组织纤溶酶原激活物(t-PA)和人纤溶酶原激活物抑制剂(PAI-1)的水平。结果 研究组患者的血管再通率为81.82%,对照组患者的血管再通率为63.64%,差异具有统计学意义(P<0.05)。治疗前,两组患者的PAI-1、t-PA、hs-CRP、IL-6及MCP-1相比,差异无统计学意义;治疗后,两组患者的hs-CRP、IL-6及MCP-1水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且研究组患者的hs-CRP、IL-6及MCP-1显著低于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者PAI-1明显降低,而t-PA显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且研究组患者PAI-1显著低于对照组,而t-PA显著高于对照组,差异具有统计学意义(P<0.05)。研究组患者的MACE发生率为6例(10.91%),对照组患者的MACE发生率为17例(30.91%),差异具有统计学意义(P<0.05)。结论 重组人尿激酶能够显著提高急性ST段抬高型心肌梗死患者的血管再通率、降低炎症反应及主要不良心血管事件的发生率。
[Key word]
[Abstract]
Objective To investigate the effect of clinical effect and inflammatory factor of prourokinase in the treatment with STsegment elevation myocardial infarction. Methods 110 cases ST-segment elevation myocardial infarction patients from March 2016 to March 2018 in our hospital, according to the random number divided into research group (55 cases) and control group (55 cases), the control group was given routined treatment, the research group was given recombinant human urokinase on the basis of routine treatment, compared with the vessel repass rate and the incidence of the major adverse cardiovascular events, and tested the level of high-sensitivity C-reactive protein, IL-6, monocyte chemo-attractant protein-1, human tissue-plasminogen activator and human plasminogen activator inhibitor 1. Results The vessel repass rate of the research group is 45 cases (81.82%), the vessel repass rate of the 35 cases (63.64%), the difference was statistically significant (P<0.05). Compared with the PAI-1, t-PA, hs-CRP, IL-6 and MCP-1 of the two groups before treatment, the difference was not statistically significant. After treatment, the PAI-1, hs-CRP, IL-6 and MCP-1 of the research group was significantly lower than control group, but the t-PA significantly increased, the difference was statistically significant (P<0.05). The incidence of MACE of the research group is 6 cases (10.91%), the incidence of MACE of the control group is 17 cases (30.91%), the difference was statistically significant (P<0.05). Conclusion Prourokinase can significantly improved the vessel repass rate of the acute ST-segment elevation myocardial infarction, and decreased the inflammatory response and the incidence of the major adverse cardiovascular events.
[中图分类号]
[基金项目]